Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, has been in the spotlight recently with its establishment on NASDAQ. On Monday, the stock opened at $6.97, with a market capitalization of 283.69 million and a beta of 2.33. Scrolling through the stock’s past few months, we can see that it holds an average 50-day moving price of $4.27 and 200-day moving average price of $3.79.
This rise in stock price has been attributed to Olema Pharmaceutical’s lead product candidate- OP-1250, which is targeted towards treating estrogen receptor-positive breast cancer patients. Currently, it is undergoing phase 1/2 clinical trials for its efficacy on patients diagnosed with recurrent locally advanced or metastatic human epidermal growth factor receptor-negative breast cancer.
Due to the ground-breaking advancements brought forth by OP-1250 in Breast Cancer Treatment, several research analysts have issued positive reports and outperform rating shares for Olema Pharmaceuticals, four out of five being Buy rating shares from equities research analysts—despite Credit Suisse Group lowering their target prices from $12 to $11 per share.
Speaking on Olema Pharmaceuticals’ financial statements and performance, they had previously disclosed earnings per share (EPS) results on March 9th earlier this year—with estimations landing at ($0.65) having reported relatively stable revenue as compared to the previous quarter’s $30 thousand.
In conclusion, Olema Pharmaceuticals Inc’s successful course on NASDAQ coupled with clinical trial breakthroughs shows promise for their mission to commercialize treatments for women’s cancers —there is no doubt that they will continue to shake up the markets around them in future data releases and industry prospects!
Capital One Financial Issues Q3 2023 EPS Estimates for Olema Pharmaceuticals Inc. (NASDAQ:OLMA)
Capital One Financial, a renowned name in the world of equities research and analysis, recently released their Q3 2023 EPS estimates for Olema Pharmaceuticals Inc. (NASDAQ:OLMA). This report was issued to clients and investors on Wednesday, May 10th, stating that the company’s earnings per share (EPS) for the quarter would be ($0.71), which is lower than their prior estimate of ($0.48).
As expected, this new update has caused quite a stir in the market among investors who hold an interest in Olema Pharmaceuticals. Capital One Financial Analyst Z. Jallah believes that this decreased EPS estimate for Q3 2023 is indicative of a slowdown in sales growth for the quarter, which presents a challenge to the company.
Furthermore, it appears that Olema Pharmaceuticals may also struggle in terms of full-year earnings as Capital One Financial predicts an EPS of ($2.77) for FY2023. Additionally, they have estimated that there will be further decreases in EPS values throughout FY2024 – eventually reaching ($3.70) by FY2027.
Despite these negative details highlighted by Capital One Financial’s report, institutional investors and hedge funds remain optimistic about OLMA’s future prospects. HRT Financial LP made a significant move in purchasing a $68,000 stake during Q1 2021 while Dimensional Fund Advisors LP raised its position by nearly 30%. Meanwhile, Citigroup Inc increased its position during Q1 by purchasing new shares worth $34k.
Tower Research Capital LLC TRC also demonstrated immense faith in Olema Pharmaceutical stocks when it lifted its position significantly in Q1 by almost 200%, now holding over 29k shares valued at $101k.
Finally, Jane Street Group LLC completed the roster of major institutional investors ready to bet on OLMA stock last year when it purchased new shares worth $28k.
As we scrutinize recent data from both Capital One Financial and institutional investor activity, it’s safe to say that the future of Olema Pharmaceuticals is uncertain, but several entities remain faithful in its ability to rebound. Further analysis into the company’s financials will help to provide more insight into their performance over the next quarter.
The post Olema Pharmaceuticals Rises on NASDAQ with Promising Breast Cancer Treatment appeared first on Best Stocks.
